Novel therapy interrupting the CXCR4-CXCL12 axis may weaken the protective role of the bone marrow microenvironment, enhance the sensibility of CML cells to TKI, and even eliminate LSC. Here, CXCR4 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.